Фибрилляция предсердий в сочетании с артериальной гипертензией: польза и риск антитромботической терапии

1. January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. JACC 2014; pii: S0735-1097(14)01740-9.
2. Баранова Е.И. Фибрилляция предсердий у больных артериальной гипертензией. Артериальная гипертензия. 2011; 17 (4): 293–304.
3. Benjamin EJ, Levy D, Vaziri SM et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271: 840–4.
4. Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354 (9192): 1751–6.
5. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353 (9153): 611–6.
6. Dahlöf B, Devereux RB, Kjeldsen SE et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359 (9311): 995–1003.
7. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008; 1 (1): 62–73.
8. Dobrev D. Electrical remodeling in atrial fibrillation. Herz 2006; 31 (2): 108–12.
9. Mayyas F, Alzoubi KH, Van Wagoner DR. Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling. Int J Cardiol 2013; 168 (6): 5135–42.
10. Pisters R, Lane DA, Marin F et al. Stroke and thromboembolism in atrial fibrillation. Circ J 2012; 76 (10): 2289–304.
11. Fang MC, Singer DE, Chang Y et al. Gender differences in the risk of ischaemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005; 112: 1687–91.
12. Lip GY, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137: 263–72.
13. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ, 2012.
14. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005; 36: 1588–93.
15. Flaherty ML. Anticoagulant-associated intracerebral hemorrhage. Semin Neurol 2010; 30 (5): 565–72.
16. Abdelhafiz AH, Wheeldon NM. Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic. Clin Therap 2004; 26: 1470–8.
17. Hankey GJ, Stevens SR, Piccini JP et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke 2014; 45 (5): 1304–12.
18. Palareti G, Cosmi B. Bleeding with anticoagulation therapy. Who is at risk, and how best to identify such patients. Thromb Haemost 2009; 102: 268–78.
19. Gage BF, Yan Y, Milligan PE et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713–9.
20. Fang MC, Go AS, Chang Y et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. JACC 2011; 58: 395–401.
21. Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093–100.
22. Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann Hematol 2011; 90: 1191–200.
23. Petersen P, Boysen G, Godtfredsen J et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1 (8631): 175–9.
24. Roskell NS, Samuel M, Noack H, Monz BU. Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies. Europace 2013; 15 (6): 787–97.
25. Flaherty ML. Anticoagulant-associated intracerebral hemorrhage. Semin Neurol 2010; 30 (5): 565–72.
26. Nekkanti H, Mateti UV, Vilakkathala R et al. Predictors of warfarin-induced bleeding in a South Indian cardiology unit. Perspect Clin Res 2012; 3 (1): 22–5.
27. Goodman SG, Wojdyla DM, Piccini JP et al. ROCKET AF Investigators. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). JACC 2014; 63 (9): 891–900.
28. Lip GY, Frison L, Grind M. SPORTIF Invetigators. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J 2007; 28 (6): 752–9.
29. Fric-Shamji EC, Shamji MF, Cole J, Benoit BG. Modifiable risk factors for intracerebral hemorrhage: study of anticoagulated patients. Can Fam Physician 2008; 54 (8): 1138–9.
30. Ho LY, Siu CW, Yue WS et al. Safety and efficacy of oral anticoagulation therapy in Chinese patients with concomitant atrial fibrillation and hypertension. J Hum Hypertens 2011; 25 (5): 304–10.
31. Abdelhafiz AH, Wheeldon NM. Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice. Am J Geriatr Pharmacother 2008; 6 (1): 1–11.
32. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEJM 2009; 361 (12): 1139–51.
33. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEJM 2011; 365 (10): 883–91.
34. Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus warfarin in patients with atrial fibrillation. NEJM 2011; 365 (11): 981–92.
35. Matsumoto M, Hori M, Tanahashi N et al. Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial. Hypertens Res 2014; 37 (5): 457–62.
36. Hankey GJ, Stevens SR, Piccini JP et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke 2014; 45 (5): 1304–12.
37. Nagarakanti R, Connolly S, Brueckmann M et al. Benefits of Dabigatran versus Warfarin in Hypertensive Patients With Atrial Fibrillation: Results From The Re-Ly Trial. Abstract N 11087 at AHA Scientific sessions 2013; 16–20 Nov; Dallas; Abstract available at http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3281&cKey=b2620b33-cc62-48e6-b06b-...
38. Flaker GC, Eikelboom JW, Shestakovska O et al. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. Stroke 2012; 43 (12): 3291–7.
39. Lip GY, Felmeden DC, Dwivedi G. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev 2011; 12: CD003186.
40. Ge L, Niu G, Han X et al. Aspirin treatment increases the risk of cerebral microbleeds. Can J Neurol Sci 2011; 38 (6): 863–8.
41. Jang SW, Rho TH, Kim DB et al. Optimal antithrombotic strategy in patients with atrial fibrillation after coronary stent implantation. Korean Circ J 2011; 41 (10): 578–82.
42. DeEugenio D, Kolman L, DeCaro M et al. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. Pharmacotherapy 2007; 27 (5): 691–6.
43. Справочник Видаль. Лекарственные препараты в России. М.: ЮБМ Медика Рус, 2014.
44. Laupacis A, Boysen G, Connolly S et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449–57.
45. Arima H, Anderson C, Omae T et al. Effects of blood pressure lowering on intracranial and extracranial bleeding in patients on antithrombotic therapy: the PROGRESS trial. Stroke 2012; 43 (6): 1675–7.
46. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–219.

К.В.Протасов

ГБОУ ДПО Иркутская государственная медицинская академия последипломного образования Минздрава России